Business Wire

Earnix Delivers on Promise of AI with Intelligent Decisioning Platform

10.9.2025 13:00:00 CEST | Business Wire | Press Release

Share

At its Excelerate 2025 conference, Earnix, the leader in Dynamic AI for insurance, announced a new suite of solutions designed to help insurers fully realise the promise of AI. Built specifically for the insurance industry, these technologies accelerate decision-making and improve personalised customer experiences all while ensuring compliance in complex regulatory environments.

For insurers, these Intelligent Decisioning capabilities unlock smarter, data-driven decision-making at scale. The platform delivers real-time insights and personalised offerings with faster speed-to-market, while maintaining robust governance of automated decisions. Customers benefit from:

  • Improved profitability and risk management
  • Stronger regulatory compliance and governance
  • Enhanced customer satisfaction through personalised engagement
  • Greater competitive positioning in a rapidly changing landscape

The unified, no-code/low-code intelligent decisioning platform empowers business users to innovate rapidly without relying on IT teams. It enables insurers to adapt quickly to market shifts, launch new products faster, and optimise pricing strategies with confidence. Seamless data integration, embedded compliance and explainability, and out-of-the-box connectivity with core systems and engagement channels ensure insurers can operate effectively even in heavily regulated settings.

Intelligent Decisioning

Earnix’s Intelligent Decisioning Platform is underpinned by Earnix’s robust data and Dynamic AI capabilities, unifying predictive, generative, and agentic AI capabilities with governed workflows so teams can act quickly and confidently and launch innovative products without compromising security, compliance, or control.

Intelligent Decisioning Solution Enhancements Announced Today:

  • Earnix’s AI Studio: Earnix’s AI Studio is a purpose-built intelligent decisioning solution designed for the insurance industry. It allows carriers to seamlessly create, manage, and deploy agentic AI within decisioning workflows, supported by an intuitive no-code/low-code environment and a catalog that governs versioning, authorisation, and control. Embedded guardrails ensure each agent operates within defined policies, while built-in testing capabilities verify reliability before deployment. With these safeguards, insurers can embed agents into their operations with confidence, ensuring governance, transparency, and trust at scale.
  • Elevate Data: Elevate Data is a unified, governed data layer for Dynamic AI that addresses growing data complexity. It provides seamless integration with major data lake providers, including AWS, Snowflake, and Databricks, and offers AI-driven ETL (extract, transform, load) capabilities. It empowers carriers to ingest, transform, and manage both proprietary and third-party data at scale, enabling better model development and faster, more informed decisioning directly aligned with regulatory standards and operational needs.
  • Customer Engagement Capabilities: Earnix’s Customer Engagement Platform leverages advanced AI to enhance front-line interactions by delivering personalised, next-best-action recommendations to agents and digital channels. The solution interacts with vertical solutions across the decisioning journey to empower sales and service teams with contextual insights, improving customer experiences, accelerating conversion, and driving revenue growth.

“The insurance industry is evolving at record speed. Changing risks, regulatory pressures, and the demand for more personalised service mean that carriers must anticipate - and enable - what’s next,” said Robin Gilthorpe, CEO at Earnix. “Our intelligent decisioning platform is purpose-built for this moment. It brings together the power of predictive, generative and agentic AI, underpinned by robust governance, and positions clients to deliver exceptional value in every market they serve.”

“The promise of AI in insurance comes with challenges - governance, compliance, and trust are non-negotiable in our industry,” commented Be’eri Mart, Chief Product Officer at Earnix. “Our AI capabilities empower carriers to operationalise agentic AI seamlessly within decisioning workflows, while embedding the insurance-specific guardrails needed to ensure reliability. This combination unlocks the ability to scale innovation responsibly, transforming underwriting, pricing, and beyond into transparent, agile, and future-ready operations.”

“Insurers today face mounting pressure to modernise their operations while harnessing the full power of their data and analytics investments. Solutions like Earnix's can help insurers embed advanced AI and automation directly into core processes - enabling organisations to accelerate innovation, improve risk assessment, and respond to changing market demands with far greater agility,” explained Keith Raymond, Principal Analyst at Celent. “These advancements not only drive operational efficiency but also lay the foundation for more personalised and responsive customer experiences across the value chain.”

About Earnix

Earnix is the premier provider of mission-critical, intelligent decisioning across pricing, underwriting, rating, and product personalisation. Its fully integrated platform provides ultra-fast ROI and is designed to transform how global insurers and banks are run by unlocking value across all facets of the business. Earnix has been innovating for insurers and banks since 2001, with customers in over 35 countries across six continents and offices in the Americas, Europe, Asia Pacific, and Israel. Earnix is backed by investors JVP and Insight Partners.

To learn more, visit: www.earnix.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250910322722/en/

Contacts

Media Contact:
Paul Dobson-Brunell
Director of Communications, Earnix
press@earnix.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye